Hasan Jafri of MedImmune and COMBACTE Magnet: Featured Speaker at World Anti-Microbial Resistance Congress USA 2016

Dr. Hasan Jafri has been involved in the design and conduct of multiple Phase 1‐4 clinical studies to assess novel small and large molecules against bacterial, viral and fungal pathogens. Prior to joining MedImmune, Dr. Jafri served as a professor in pediatric infectious diseases and clinical science research at the University of Texas Southwestern Medical Center at Dallas. He was …

Ribhi Shawar of FDA: Featured Speaker at World Anti-Microbial Resistance Congress USA 2016

Dr. Ribhi Shawar currently serves as the Branch Chief at the Division of Microbiology in the Office of In vitro Diagnostic and Radiological Health (OIR) at the Center for Devices and Radiological Health (CDRH) at FDA where he specializes in the area of antimicrobial susceptibility testing and detection of resistance. Dr. Shawar has a Ph.D. in Medical Microbiology and an M.Sc. in …

Jens Eckstein of SR One: Featured Speaker at World Anti-Microbial Resistance Congress USA 2016

Dr. Eckstein, President, comes to SR One from TVM Capital where he was a Venture Partner, Entrepreneur-in-Residence and appointed CEO and President of SelectX Pharmaceuticals. Prior to that, he was a General Partner in TVMs Boston life sciences practice where he focused on earlier-stage investments. He is currently a Director of Thrasos Therapeutics, Palleon Pharma, Decibel Therapeutics, Gladius Pharmaceuticals and …

Anders Karlén of Uppsala University: Featured Speaker at World Anti-Microbial Resistance Congress

Anders Karlén, Professor in Computer-aided drug design, Uppsala University, Sweden, is presently the overall medicinal chemistry project leader for drug discovery efforts currently directed at five different anti-bacterial targets at Uppsala University. Several of these projects have been run within EU framework 6 and 7 programmes. Since February 2014 he is the Leader of the Managing Entity and co-coordinator of the …

Jane Knisely of NIH-NIAID: Featured Speaker at World Anti-Microbial Resistance Congress USA 2016

Jane Knisely is a Program Officer in the Bacteriology and Mycology Branch of the Division of Microbiology and Infectious Diseases at the National Institute of Allergy and Infectious Disease, NIH, where she oversees scientific programs related to antimicrobial resistance and antibacterial drug development. Specifically, Jane is the program officer for NIAID’s Antibacterial Resistance Leadership Group, a clinical trials group focused …

Evolving existing drug classes to meet the challenges of unmet medical needs: navigating regulatory perspectives

“Evolving existing drug classes to meet the challenge of unmet medical needs: navigating regulatory perspectives “

Mark Jones, PhD, Head of Project Management at Basilea Pharmaceutica joined us for World Anti-Microbial Resistance Congress USA 2015 to discuss ‘navigating regulatory perspectives ‘. In this presentation, learn about navigating regulatory perspectives in the context of the unmet medical need for new antifungals . Download the presentation to understand more about: Where will our new antifungals come from? The …

David Mantus: Featured Speaker at World Anti-Microbial Resistance Congress USA 2016

David Mantus of Arsanis: Featured Speaker at World Anti-Microbial Resistance Congress USA 2016

David Mantus, Ph.D. is Chief Development Officer at Arsanis, Inc., a clinical stage biotechnology company developing monoclonal antibodies to prevent and treat serious bacterial infections. He has more than 24 years of drug development experience, including clinical, regulatory and manufacturing successes for programs in endocrinology, central nervous disorders, and infectious disease. His work in infectious disease product development has included …

Judy Hackett of AstraZeneca: Featured Speaker at World Anti-Microbial Resistance Congress USA 2016

Judy Hackett received her Pharmacy Degree from the University of Toronto.  She subsequently completed her M.B.A. at York University.  As well she has a graduate degree in Evaluation and Outcomes from the Faculty of Medicine,  University of Toronto. She began her career working in community pharmacy and then went onto work as a payer where she developed and managed drug …

Crestone: Novel Drug Discovery Programs for Infectious Diseases

“Crestone: Novel Drug Discovery Programs For Emerging Infectious Diseases”

Thale Jarvis of Crestone joined us for World Anti-Microbial Resistance Congress USA 2015 to discuss ‘novel drug discovery programs for emerging infectious diseases’. In this presentation, learn about CRS3123 for the treatment of Clostridium difficile infections. Download the presentation to understand more about: Crestone’s mission Clostridium difficile infection (CDI) CRS3123: Key advantages vs. competition …and much more! Get your copy …

Chris Houchens of BARDA: Featured Speaker at World Anti-Microbial Resistance Congress USA 2016

Christopher Houchens, PhD joined the US Government’s Biomedical Advanced Research and Development Authority (BARDA) in April 2012. In his previous role as a BARDA Project Officer, Chris lead multiple interdisciplinary product development teams responsible for advancing the development, manufacture, clinical and non-clinical evaluation, and regulatory approval of novel drugs against multidrug resistant organisms, emerging infectious diseases and biothreat agents. In …